GRAIL has developed a multicancer early detection blood tests that includes pancreatic and liver cancers called Galleri. Their PATHFINDER clinical trial (NCT04241796) included 6662 participants and assessed the time required and the diagnostic testing necessary to confirm the presence or absence of cancer. Recently published results revealed that 1.4% of participants received a positive result. Of those positive results, 38% were true positives and would go on to get a positive cancer diagnosis with further screening. 211 GRAIL will continue this research with a PATHFIDER 2 clinical trial (NCT05155605), currently recruiting, to further access the safety and performance of the Galleri test. Mirxes is another company researching early multi-cancer detection and is currently recruiting for their CADENCE (CAncer Detected Early caN be CureEd) clinical trial (NCT05633342). This study will develop a blood based multicancer screening test to detect nine of the most prevalent cancers in Singapore including pancreatic and liver. The three-year study will investigate microRNA expression with other biomarkers such as DNA methylation amongst 20,000 participants.